Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

November 14, 2011
PublicationTivozanib

Biological and Clinical Activity of Tivozanib, a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4 Week on, 2 Week off Schedule in Patients With Advanced Solid Tumors.

Authors: Ferry A. L. M. Eskens, Maja J. A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, Jaap Verweij. Click here for link to article.

November 13, 2011
PresentationTivozanib

AACR-NCI-EORTC 2011: Tivozanib, a selective VEGFR TKI, potently blocks angiogenesis and growth in tumors that express a high level of VEGF-C and are refractory to VEGF-A blockade

November 6, 2011
PresentationTivozanib

EMUC 2011 – Results from Phase 1 trial of tivozanib combined with temsirolimus in patients with RCC

June 7, 2011
PresentationTivozanib

ASCO 2011: Final Analysis of the Phase 2 Randomized Discontinuation Trial of Tivozanib (AV-951) Versus Placebo in Patients With Renal Cell Carcinoma

June 7, 2011
PresentationTivozanib

ASCO 2011: Results From a Phase 1 Trial of Tivozanib (AV-951) Combined With Temsirolimus Therapy in Patients With Renal Cell Carcinoma

June 6, 2011
PresentationFiclatuzumab

ASCO 2011: Phase 2 Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With Non–Small Cell Lung Cancer

1 … 11 12 13 14 15

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.